<a href="https://laohu8.com/S/SLP">Simulations Plus</a> Unveils ADMET Predictor 13, Enhancing AI/ML Capabilities for Drug Discovery
Simulations Plus, Inc., a leader in cheminformatics and biosimulation solutions for the biopharma industry, has announced the release of ADMET Predictor® 13, their advanced machine learning modeling platform. This latest version enhances functionality and AI/ML capabilities, promising faster, more precise predictions in drug discovery. The platform's advancements focus on three main areas: enhanced high-throughput PBPK simulations for improved decision-making, an expanded suite of ADMET models for heightened predictive accuracy, and enterprise-ready automation features to support data-centric R&D teams. These innovations aim to streamline drug design, optimization, and selection processes, reinforcing Simulations Plus's commitment to scientific rigor and efficiency in pharmaceutical research.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605621409) on June 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。